13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001425738
Total reported value
$1.5B
$1.5B
34 檔
53.8%
During the Q4 2025 filing period, Redmile Group, LLC (CIK: 0001425738) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $1.5B across 34 reported positions.
In Q4 2025, Redmile Group, LLC adopted a defensive or profit-taking posture, trimming 10 positions and completely liquidating 9 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SRRK | Scholar Rock Holding CORP | Stock-Other | 16.94% | -13.59% | +33.72% | |
| 2 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 12.30% | +4.25% | +2.47% | |
| 3 | NRIX | Nurix Therapeutics Inc | Stock-Other | 11.31% | -1.30% | +120.04% | |
| 4 | STOK | Stoke Therapeutics Inc | Stock-Other | 9.43% | -0.31% | -3.39% | |
| 5 | IMNM | Immunome Inc | Stock-Other | 9.05% | -1.06% | +13.84% | |
| 6 | RGNX | Regenxbio Inc | Stock-Other | 4.63% | +1.09% | -6.92% | |
| 7 | ✓ | Adc Therapeutics SA | Stock-Other | 4.07% | -3.01% | — | |
| 8 | COGT | Cogent Biosciences Inc | Stock-Other | 3.76% | -0.44% | -34.91% | |
| 9 | ANNX | Annexon Inc | Stock-Other | 3.72% | -0.79% | +59.52% | |
| 10 | BEAM | Beam Therapeutics Inc | Stock-Other | 2.62% | +0.73% | -7.33% | |
| 11 | NGNE | Neurogene Inc | Stock-Other | 2.21% | +1.03% | +12.36% | |
| 12 | RAPT | Rapt Therapeutics Inc | Stock-Other | 2.21% | — | +60.32% | |
| 13 | ABSI | Absci CORP | Stock-Other | 2.12% | +3.60% | — | |
| 14 | NUVB | Nuvation Bio Inc | Stock-Other | 2.09% | +0.26% | +4.36% | |
| 15 | IDYA | Ideaya Biosciences Inc | Stock-Other | 1.89% | +0.45% | — | |
| 16 | STTK | Shattuck Labs Inc | Stock-Other | 1.49% | +0.85% | — | |
| 17 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.97% | +0.84% | — | |
| 18 | ZYME | Zymeworks Inc | Stock-Other | 0.95% | +0.04% | -86.73% | |
| 19 | FATE | Fate Therapeutics Inc | Stock-Other | 0.93% | +1.31% | — | |
| 20 | REPL | Replimune Group Inc | Stock-Other | 0.79% | — | +105.25% | |
| 21 | DBVT | Dbv Technologies Sa-spon Adr | Stock-Other | 0.78% | -0.23% | — | |
| 22 | SLDB | Solid Biosciences Inc | Stock-Other | 0.77% | +0.35% | -2.04% | |
| 23 | CBLL | Ceribell Inc | Stock-Other | 0.70% | +0.04% | — | |
| 24 | ✓ | Establishment Labs Holdings In | Stock-Other | 0.60% | +0.12% | -12.91% | |
| 25 | ATRA | Atara Biotherapeutics Inc | Stock-Other | 0.59% | +0.20% | — | |
| 26 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.57% | +0.53% | -13.36% | |
| 27 | LIVN | LivaNova PLC | Stock-Other | 0.53% | +0.05% | -87.26% | |
| 28 | IVVD | Invivyd Inc | Stock-Other | 0.49% | -0.08% | +17.32% | |
| 29 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.44% | -0.08% | — | |
| 30 | RPTX | Repare Therapeutics Inc | Stock-Other | 0.30% | — | — | |
| 31 | ALXO | Alx Oncology Holdings Inc | Stock-Other | 0.27% | -0.03% | -2.05% | |
| 32 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 0.27% | -0.09% | — | |
| 33 | PLRX | Pliant Therapeutics Inc | Stock-Other | 0.15% | — | +1.54% | |
| 34 | KLRS | Kalaris Therapeutics Inc | Stock-Other | 0.05% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NRIX | Nurix Therapeutics Inc | +8% | +120.04% | Add |
| 2 | IMNM | Immunome Inc | +3.3% | +13.84% | Add |
| 3 | SRRK | Scholar Rock Holding CORP | +2.8% | +33.72% | Add |
| 4 | ANNX | Annexon Inc | +1.9% | +59.52% | Add |
| 5 | NUVB | Nuvation Bio Inc | +1% | +4.36% | Add |
| 6 | KRYS | Krystal Biotech Inc | +0.9% | +2.47% | Add |
| 7 | RAPT | Rapt Therapeutics Inc | +0.8% | +60.32% | Add |
| 8 | COGT | Cogent Biosciences Inc | +0.7% | -34.91% | Trim |
| 9 | REPL | Replimune Group Inc | +0.6% | +105.25% | Add |
| 10 | IVVD | Invivyd Inc | +0.3% | +17.32% | Add |
| 11 | RGNX | Regenxbio Inc | +0.2% | -6.92% | Trim |
| 12 | CBLL | Ceribell Inc | +0.2% | — | Unchanged |
| 13 | STTK | Shattuck Labs Inc | +0.2% | — | Unchanged |
| 14 | ✓ | Establishment Labs Holdings In | +0.1% | -12.91% | Trim |
| 15 | RPTX | Repare Therapeutics Inc | 0% | — | Unchanged |
| 16 | NGNE | Neurogene Inc | 0% | +12.36% | Add |
| 17 | KLRS | Kalaris Therapeutics Inc | — | — | Unchanged |
| 18 | ATRA | Atara Biotherapeutics Inc | 0% | — | Unchanged |
| 19 | IDYA | Ideaya Biosciences Inc | -0.1% | — | Unchanged |
| 20 | PLRX | Pliant Therapeutics Inc | -0.1% | +1.54% | Add |
| 21 | STOK | Stoke Therapeutics Inc | -0.1% | -3.39% | Trim |
| 22 | SLN | Silence Therapeutics Plc-adr | -0.1% | — | Unchanged |
| 23 | CLDX | Celldex Therapeutics Inc | -0.3% | -13.36% | Trim |
| 24 | ABSI | Absci CORP | -0.3% | — | Unchanged |
| 25 | ALXO | Alx Oncology Holdings Inc | -0.3% | -2.05% | Trim |
| 26 | SLDB | Solid Biosciences Inc | -0.4% | -2.04% | Trim |
| 27 | FATE | Fate Therapeutics Inc | -0.7% | — | Unchanged |
| 28 | BEAM | Beam Therapeutics Inc | -0.7% | -7.33% | Trim |
| 29 | ✓ | Adc Therapeutics SA | -2% | — | Unchanged |
| 30 | LIVN | LivaNova PLC | -4.2% | -87.26% | Trim |
| 31 | ZYME | Zymeworks Inc | -5.2% | -86.73% | Trim |
| 32 | AKRO | Akero Therapeutics Inc | — | EXIT | Sold out |
| 33 | ETNBGBP | 89bio Inc | — | EXIT | Sold out |
| 34 | DBVT | Dbv Technologies Sa-spon Adr | — | NEW | New buy |
| 35 | KROS | Keros Therapeutics Inc | — | EXIT | Sold out |
| 36 | AM6 | Amicus Therapeutics Inc | — | EXIT | Sold out |
| 37 | XENE | Xenon Pharmaceuticals Inc | — | NEW | New buy |
| 38 | XERS | Xeris Biopharma Holdings Inc | — | EXIT | Sold out |
| 39 | ORIC | Oric Pharmaceuticals Inc | — | NEW | New buy |
| 40 | VTYXUSD | Ventyx Biosciences Inc | — | EXIT | Sold out |
| 41 | ✓ | Lava Therapeutics NV | — | EXIT | Sold out |
| 42 | PRME | Prime Medicine Inc | — | EXIT | Sold out |
| 43 | BOLD | Boundless Bio Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Redmile Group, LLC reported a total U.S. public equity portfolio value of $1.5B across 34 disclosed positions in Q4 2025.
During Q4 2025, Redmile Group, LLC's top holdings by market value included SRRK (16.9%)、KRYS (12.3%)、NRIX (11.3%). The largest single position, SRRK, represented 16.9% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SRRK, KRYS, NRIX) accounted for 53.8% of total reported equity market value during Q4 2025.
Top New Position Initiated
DBVT
市值: $10.5M
Top Position Liquidated / Trimmed
AKRO
前期市值: $35.5M
In Q4 2025, Redmile Group, LLC made 33 total portfolio adjustments, initiating 3 new buys, adding to 11 positions, trimming 10 holdings, and fully liquidating 9 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.